NCT00644579

bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients

bLAC - A Phase II Double-Blind, Placebo Controlled, Clinical Proof of Concept Trial of the Efficacy of 8 Weeks Treatment of Cutaneous Warts With bLAC in Immune Suppressed, Kidney Transplanted Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: NatImmune A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

As many as 85 % of renal transplant patients may suffer from viral warts with a high degree of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid) point to a beneficial effect without noticeable side effects of bLAC (bovine lactalbumin complex with lipid). The aim of first clinical trial with bLAC is to show proof of concept in treatment of cutaneous wart lesions on hands and/or feet after local administration of bLAC in two dose groups to immune suppressed, kidney transplanted patients.

Conditions

• Cutaneous Warts

Interventions

Type	Name	Description
DRUG	bLAC	bLAC high and low dose and placebo
DRUG	Placebo	Placebo

Timeline

• Start date: 2008-03-01
• Primary completion: 2008-12-01
• Completion: 2009-02-01
• First posted: 2008-03-27
• Last updated: 2008-03-27

Locations

5 sites across 1 country: Denmark